Bavarian Nordic (OTCMKTS:BVNRY) Releases Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) released its quarterly earnings data on Friday. The company reported $0.72 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $281.11 million for the quarter. Bavarian Nordic had a return on equity of 12.35% and a net margin of 21.95%.

Bavarian Nordic Price Performance

Shares of Bavarian Nordic stock traded down $0.57 during trading on Friday, hitting $9.09. 4,654 shares of the company’s stock traded hands, compared to its average volume of 6,711. The company has a market cap of $2.16 billion, a PE ratio of 10.45 and a beta of 1.23. The firm’s fifty day moving average price is $11.79 and its 200 day moving average price is $10.61. Bavarian Nordic has a twelve month low of $6.60 and a twelve month high of $13.00.

Bavarian Nordic Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.